MacroGenics Inc ( (MGNX) ) has released its Q3 earnings. Here is a breakdown of the information MacroGenics Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the development of innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary suite of antibody technology platforms.
In its latest earnings report for the quarter ended September 30, 2025, MacroGenics, Inc. reported total revenues of $72.8 million, a decrease from $110.7 million in the same quarter of the previous year. The company’s net income for the quarter was $16.8 million, compared to $56.3 million in the prior year, reflecting a significant decline in profitability.
Key financial metrics from the report indicate a substantial drop in collaborative and other agreement revenues, which fell to $53 million from $101.4 million year-over-year. Additionally, product sales were non-existent this quarter compared to $4.1 million in the previous year. However, contract manufacturing revenues saw an increase, reaching $19.8 million from $4.6 million. The company also reported a significant increase in accounts receivable and a new liability related to future royalties, impacting its financial position.
Looking forward, MacroGenics, Inc. remains focused on advancing its proprietary product candidates in clinical development, including lorigerlimab, MGC026, and MGC028. The management anticipates relying on strategic collaborations and potential new capital to support ongoing research and development efforts, aiming to maintain sufficient resources to fund operations for at least the next twelve months.